Literature DB >> 12563380

Progressive supranuclear palsy in a sample of Brazilian population: clinical features of 16 patients.

Paulo Eduardo Mestrinelli Carrilho1, Egberto Reis Barbosa.   

Abstract

Progressive supranuclear palsy (PSP) is an uncommon disorder characterized by marked postural instability, vertical gaze abnormalities and axial rigidity. The purpose of this study is to report the clinical features of 16 consecutive subjects seen over a 10-year period at a Movement Disorders Clinic. These subjects fulfilled criteria for probable PSP namely those of the National Institute of Neurologic Disorders and Stroke (NINDS) and the Society for PSP (SPSP). This patient-group represented 2.1% of all degenerative parkinsonians observed and the mean age of onset of the disease was 64.7 years (sd = +/- 7.2). Postural instability with falls was the most frequent initial feature presented in PSP patients (62.5%). The hallmark of the disease, the supranuclear vertical gaze palsy, appeared after 2.3 years of disease onset, and only 12.5% had such manifestation at the first evaluation. Transient tremor was observed with a relatively high frequency in this group (44%), but only 19% had rest tremor. Chronic dacryocystitis, probably related to a paucity of blinking, was observed in two patients as an inaugural manifestation. In the first evaluation, only 19% of the 16 patients were diagnosed as probable PSP. The mean interval prior to the final diagnosis was 2.4 years.

Entities:  

Mesh:

Year:  2003        PMID: 12563380     DOI: 10.1590/s0004-282x2002000600006

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  5 in total

1.  In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS.

Authors:  Jitender Saini; Bhavani Shankara Bagepally; Mangalore Sandhya; Shaik Afsar Pasha; Ravi Yadav; Pramod Kumar Pal
Journal:  Neuroradiology       Date:  2011-12-09       Impact factor: 2.804

2.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

Review 3.  A Review of Treatment Options for Progressive Supranuclear Palsy.

Authors:  Maria Stamelou; Günter Höglinger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

4.  A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy.

Authors:  Boyd C P Ghosh; Roger H S Carpenter; James B Rowe
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

5.  Clinical features and disability milestones in multiple system atrophy and progressive supranuclear palsy.

Authors:  Sang-Wook Lee; Seong-Beom Koh
Journal:  J Mov Disord       Date:  2012-10-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.